CEACAM5 and cancer: Importantly, in the diagnosis of early-stage cancers, the m5C-miRNA signature had significantly better detection ability than traditional biomarkers, such as prostate-specific antigen, carcinoma antigen 125, carbohydrate antigen 72-4, carcinoembryonic antigen, and carbohydrate antigen 19-9 (43, 44).